Evidence map›Paper›PMID 38429605›Full record

ArticleMolecular biology reports2024

Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance.

Nima Mohammadipoor, Raika Naiebi, Seyed Amirhossein Mazhari, Fateme Amooei, Marzieh Owrang, Sahar Dastghaib, Mesbah Shams, Mohammad Hassan Maleki, Sanaz Dastghaib

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Nima Mohammadipoor *Department of Nutrition, School of Public Health, Iran University of Medical Science, Tehran, Iran.
Raika Naiebi *Department of Hematology and Blood Banking, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Seyed Amirhossein MazhariStudent Research Committee, Azerbaijan Medical University, Baku, Azerbaijan.
Fateme AmooeiDepartment of Anatomical Sciences, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Marzieh OwrangDepartment of Anatomical Sciences, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Sahar DastghaibSchool of Neurobiology Sciences, University of Utah, Salt Lake City, UT, 84112, USA.
Mesbah ShamsEndocrinology and Metabolism Research Center, Shiraz University of Medical Science, P.O. Box: 71345-1744, Shiraz, Iran.
Mohammad Hassan MalekiDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, P.O. Box: 71348-45794, Shiraz, Iran. mhmdmaleki110@gmail.com.ORCID http://orcid.org/0000-0002-0095-4264
Sanaz DastghaibEndocrinology and Metabolism Research Center, Shiraz University of Medical Science, P.O. Box: 71345-1744, Shiraz, Iran. suny.respina@gmail.com.ORCID http://orcid.org/0000-0001-8553-9221
Shiraz University of Medical Sciences · IRShiraz University · IRAzerbaijan Medical University · AZIran University of Medical Sciences · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is a form of kidney cancer characterized by dysregulated angiogenesis and multidrug resistance. Hypoxia-induced tumor progression plays a crucial role in ccRCC pathogenesis. Beta-hydroxybutyrate (BHB) and quercetin (QCT) have shown potential in targeting angiogenesis and drug resistance in various cancer types. This study investigates the combined effects of BHB and QCT in hypoxia-induced Caki-1 cells.

methodsCaki-1 cells were subjected to normoxic and hypoxic conditions and treated with BHB, QCT, or a combination of both. Cell-viability was assessed using the MTT assay, and mRNA expression levels of key angiogenesis-related genes (HIF-1α/2α, VEGF, Ang-1, Ang-2, and MDR4) were quantified through real-time PCR during 24 and 48 h.

resultsBHB and QCT treatments, either alone or in combination, significantly reduced cell-viability in Caki-1 cells (p < 0.05). Moreover, the combined therapy demonstrated a potential effect in downregulating the expression of angiogenesis-related genes and MDR4 in hypoxia-induced cells, with a marked reduction in HIF-1α/2α, VEGF, Ang-1, and MDR4 expression (p < 0.05). The expression of Ang-2 increases significantly in presence of BHB combined QCT treatment.

conclusionThis study highlights the promising potential of a combination therapy involving BHB and QCT in mitigating angiogenesis and MDR4 expression in hypoxia-induced ccRCC cells. These findings support further investigation into the underlying mechanisms and warrant clinical studies to evaluate the therapeutic value of this combined treatment for ccRCC patients. This research provides new insights into addressing the challenges posed by angiogenesis and drug resistance in ccRCC.

Indexed as

Carcinoma, Renal CellKidney Neoplasms3-Hydroxybutyric AcidAngiogenesisDrug Resistance, MultipleHumansHypoxiaQuercetinVascular Endothelial Growth Factor A3-Hydroxybutyric AcidQuercetinVascular Endothelial Growth Factor AAngiogenesisClear cell renal cell carcinomaHIF-αQuercetinβ-Hydroxybutyrate

Identifiers

PMID38429605
OpenAlexW4392345607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.